Bazi Jinhua Powder Veterinary Grade API is supplied under model designations BJH-VET-PDR-01 for oral solid dosage forms, BJH-VET-PDR-02 for parenteral-grade preparation, and BJH-VET-PDR-03 for feed premix and granule dilution. The material is a dry, free-flowing powder intended for direct compression, wet granulation, capsule filling, dry powder filling, granule blending, premix production, and reconstitution into oral or injectable solutions. Identity is established against a certified reference standard by infrared absorption and high-performance liquid chromatography retention time according to USP <621>. Assay is reported on the dried basis; loss on drying is determined by Ph. Eur. 2.2.32. Residual solvents are controlled under USP <467> and VICH GL18. Elemental impurities are assessed using USP <232>/<233> with limits selected by finished dosage route. Oral grade BJH-VET-PDR-01 is controlled to a total aerobic microbial count of 10³ CFU/g and a combined yeast and mould count of 10² CFU/g under Ph. Eur. 5.1.4. Parenteral grade BJH-VET-PDR-02 is controlled to a total aerobic microbial count of 10² CFU/g and a bacterial endotoxin limit of 0.5 EU/mg under Ph. Eur. 5.1.4 and USP <85>. The difference between grades is not an increase in chemical purity; it is a reduction in bioburden, endotoxin, and coarse particulate loading required for sterile filtration and terminal sterilization. BJH-VET-PDR-03 for premix is released with a wider particle size distribution and a higher loose bulk density specification to reduce dusting during feed-mill transfer, but the same marker compound assay and residual solvent limits apply.

Commodity powders marketed for feed use often lack the parenteral-grade endotoxin data needed for injectable manufacturing. The difference between BJH-VET-PDR-01 and BJH-VET-PDR-02 is therefore the documented removal of Gram-negative bacterial lipopolysaccharide through a controlled purification step. The purification step is not a declaration of sterility; it is a reduction of pyrogen load before terminal processing. The API is not sterile. For injectable manufacture, the final drug product must still be sterilized by moist heat or filtration, and depyrogenation of equipment is required. The bacterial endotoxin limit of 0.5 EU/mg is suitable for veterinary parenterals when the maximum daily dose does not exceed 5 mg/kg body weight; for higher doses, the formulator must calculate endotoxin burden against USP <85> and the target species limit.

How Does the Powder Perform Across Different Finished-Dosage Routes?

Performance is not a single property; it is the intersection of particle size, moisture, flow, and chemical stability under the shear, pressure and thermal conditions of each downstream process. In tablet manufacturing, BJH-VET-PDR-01 is milled through a conical screen mill fitted with a 0.8 mm rasp screen; this step breaks soft agglomerates but does not generate the fines below 20 μm that cause capping and die-fill variability. A rotary tablet press with precompression is preferred because the material exhibits plastic deformation; precompression force in the range of 3–5 kN is typically employed for 10 mm round tooling, but the exact setting depends on tablet hardness and disintegration requirements. Content uniformity is evaluated according to USP <905>, and dissolution is evaluated using USP <711> apparatus II at 50 rpm in a medium selected by the finished product dossier. For low-dose tablets with drug load below 10 mg per unit, segregation of the API before compression is a critical source of superpotent and subpotent tablets. The blend is sampled from the hopper at time zero, middle and end of compression; the acceptance criterion is that the relative standard deviation of the assay remains below 5%. If it does not, the formulation is changed to a roller-compacted granulation rather than direct compression. Roller compaction is operated at roll pressure of 4–8 MPa; ribbons are milled through a 1.0 mm screen. This route is chosen when the API’s D50 is below 50 μm and direct compression flow is inadequate. Tablet hardness is monitored with a diametral tester; hardness values of 40–60 N are typical for 10 mm round tablets, but this is formulation-specific.

For capsule filling, the powder is pre-blended in a twin-shell V-blender operated at 12 rpm for 15 min per 50 kg load; the lubrication step uses magnesium stearate screened through a 0.5 mm sieve and blended for an additional 3 min to avoid over-lubrication. Capsule fill weight is controlled by tamping pin settings; bulk density and flow function coefficient are characterized by USP <1174>. When the formulation is wet-granulated, the API is added to the high-shear granulator before the binder solution; spray rate and impeller tip speed are adjusted so that the product temperature remains below 40 °C, above which marker degradation accelerates. Granule drying in a fluid-bed dryer with inlet air temperature of 60–70 °C is stopped at a moisture content of 2–4% for oral powders, depending on the binder system.

When the same active ingredient is specified for injectable solutions, BJH-VET-PDR-02 is preferred because the lower bioburden and endotoxin load simplify sterile filtration. The powder is reconstituted in Water for Injection under a nitrogen overlay, and the solution is passed through a 0.45 μm prefilter followed by a 0.22 μm sterilizing-grade membrane filter. Terminal sterilization by moist heat is not assumed to be compatible with all formulations; published data for this specific configuration is limited, so thermal stability studies at 121 °C for 15 min are required before autoclave cycles can be selected. The acceptance criteria for subvisible particles follow USP <788> for large-volume parenterals or USP <789> for small-volume parenterals; container closure integrity is verified by dye ingress or vacuum decay according to USP <1207>. Solutions intended for oral drench or drinking water are prepared from BJH-VET-PDR-01 or BJH-VET-PDR-03; these solutions are not required to meet USP <788> limits, but the API must still pass Ph. Eur. 5.1.4 and heavy metal limits appropriate to the target species.

Particle Size Distribution, Moisture Sensitivity and Blend Segregation Risks

Particle size distribution is controlled by laser diffraction under Ph. Eur. 2.9.31. The acceptance range is deliberately narrow for oral solid dosage forms: a D50 of 75–125 μm and a D90 below 200 μm are typical for direct compression, while premix grade BJH-VET-PDR-03 permits a D90 up to 400 μm because carrier-based segregation is less dependent on cohesive forces. Overmilling below a D10 of 20 μm increases specific surface area and moisture uptake; this is measured by dynamic vapor sorption at 40% RH and 25 °C. If the API is stored at relative humidity above 60%, pre-drying is required before tableting because water acts as a plasticizer and increases capping risk. Drying in a vacuum tray dryer at 40–45 °C for 4–6 h is sufficient when the moisture specification is exceeded, but this must be validated for each batch because overlay temperature above 50 °C can change the marker compound profile.

In a production-scale capsule filling machine with dosator nozzles, a D90 above 250 μm produces blocked dosator pins and fill weight variation exceeding ±5%; a D10 below 20 μm creates dust and static adhesion to the dosator wall. The corrective action is not to use glidant alone; the API is re-milled under nitrogen with a classifier speed set to maintain the specified D10/D90 envelope. This re-milling is validated because over-milling can increase amorphous content, and amorphous domains can recrystallize during storage and change dissolution performance.

Blend segregation is addressed through bulk density matching. If the excipient bulk density differs from the API bulk density by more than 0.2 g/cm³, vibration-induced segregation is likely during tablet press hopper feeding. The product dossier therefore specifies loose bulk density and tapped density according to USP <616>; the Hausner ratio is used as a release indicator. Values between 1.15 and 1.35 are considered acceptable for capsule and tablet blends; below 1.15 the powder may flood, and above 1.35 cohesive arching becomes probable in low-shear feeders. These limits are not product-specific stability limits; they are process capability boundaries established from single-screw and twin-screw loss-in-weight feeder trials.

In feed premix operations, the powder is mixed with a carrier such as calcium carbonate or wheat middlings in a horizontal ribbon blender. The blend is sampled at multiple points after 10 min mixing; the coefficient of variation for marker compound content is used to confirm compliance with VICH GL18 homogeneity expectations. Published data for this specific configuration is limited; therefore, hold-time studies must be performed on the actual equipment because electrostatic charging of the powder can create rat-holing in silo discharge. If the environment exceeds 55% RH, the powder may agglomerate on screw augers; anti-caking agents should be evaluated for compatibility before use.

If Oral Premix and Feed-Grade Blending Conditions Are Used, What Specification Variables Must Be Controlled?

The premix grade BJH-VET-PDR-03 is not simply a sieved version of the oral grade. It is released with a wider particle size range, a higher tapped density specification, and a lower specific surface area requirement. The intention is to reduce segregation when the API is diluted 1:100 or 1:1000 in a feed carrier. In a typical pilot-scale ribbon blender with a 250 kg working capacity, sample points are collected from the top, middle and bottom of the blender; the acceptance criterion is a relative standard deviation below 5% for the marker compound. Carryover after cleaning is evaluated by wipe sampling and high-performance liquid chromatography; the limit is set in accordance with the residue acceptance criteria in VICH GL18 and the local feed safety authority. If the same powder is used for oral granules, the granule particle size is not controlled by the API alone; binder type and spray rate dominate. For this reason, the API release certificate includes sieve analysis rather than only laser diffraction data, because sieve analysis is more directly predictive of dry blending behavior in farm-scale mixers.

Compared with single-route chemical APIs, the product requires less reformulation when transitioning from oral tablets to premix because the same marker compound assay is retained; however, the physical grade differs. Compared with commodity feed-grade powders, the parenteral grade is accompanied by a bacterial endotoxin certificate and a subvisible particle risk assessment; commodity feed powders are not evaluated for USP <788> conformance. The trade-off is that BJH-VET-PDR-02 cannot be simply taken from BJH-VET-PDR-01 through sieving; separate purification and drying steps are applied. This is an operational difference, not merely a label difference. The purified parenteral grade has a lower total ash specification and a lower heavy metal limit than the premix grade, which is reflected in the certificate of analysis.

Standardized HPLC Marker Assays and Residual Solvent Control Differentiate the Product

The release method uses high-performance liquid chromatography with detection at a wavelength selected from the marker compound’s absorption maximum. System suitability follows USP <621>; the resolution between the marker compound and the nearest specified impurity is not less than 1.5. Quantification is performed against a certified reference standard, and the assay is expressed on the dried basis. This approach differs from non-specific ultraviolet spectrophotometric methods still used for commodity botanical powders; overlapping excipients may underestimate assay if not chromatographically resolved. Residual solvent control follows USP <467>; only Class 3 solvents are accepted unless the finished product dossier assigns a qualified limit for a required solvent. Packaging is aluminium-foil laminate with nitrogen overlay, and desiccant is inserted when the product is shipped to regions where average relative humidity exceeds 60%.

Operational boundaries are significant. The powder should not be mixed with strong oxidizing agents or exposed to open flame because fine organic dust can form an explosive atmosphere; dust-collection systems must be grounded and assessed under ATEX 1999/92/EC where applicable. The product is not compatible with amine-based excipients if they generate alkaline microenvironments that accelerate marker degradation. Avoid direct contact with moisture during sampling; sample containers must be reclosed under inert gas if the product is stored above 25 °C for more than 30 days. Long-term stability is conducted at 25 °C/60% RH and accelerated stability at 40 °C/75% RH according to VICH GL5; the retest period is assigned from the resulting data. For bulk powder stored in the original foil laminate container, the retest period is 24 months for BJH-VET-PDR-01 and 18 months for BJH-VET-PDR-02, unless regional stability data require a shorter period. Opened containers should be reclosed under nitrogen and used within 30 days; if desiccant is spent, the powder must be re-dried and re-tested for moisture before use.

The API is intended solely for further processing into authorized veterinary medicinal products or compounded preparations under veterinary supervision. It is not approved as a finished drug. Without formulation, the powder must not be administered directly. Species target, indication, withdrawal period, and maximum residue limits are defined by the finished product authorization, not by the API certificate of analysis. In regions where formaldehyde-releasing preservatives are permitted in oral drench solutions, compatibility data should be generated before storage; the powder may interact with formaldehyde donors and produce adducts that reduce assay recovery. Published data for this specific configuration is limited. Each batch is accompanied by a certificate of analysis listing the model code, grade, retest date, and the methods used.